Key Highlights

  • Fiscal fourth-quarter Revenue slipped to USD 12.9 million from USD 15.1 million, and the net loss came in at USD 23.7 million, or USD 0.81 a diluted share.
  • Full-year revenue was USD 63.0 million against USD 65.3 million, while the year's net loss shrank to USD 68.2 million, equal to USD 2.35 per share, down from USD 81.9 million.
  • Cash and marketable securities of USD 194.5 million at September 30, 2026 are projected to cover operations into fiscal 2029, alongside retained royalties.
  • A European court invalidated a Patent in the Paxlovid dispute in October, while the company trimmed staff by roughly one-third and announced the CEO's retirement.

Royalty Erosion and a Wider Quarterly Deficit

Enanta Pharmaceuticals (NASDAQ:ENTA) released its fiscal fourth-quarter and full-year figures on November 16, 2026. Based in Watertown, Massachusetts, the firm develops small molecule medicines for viral infections and immune disorders while still at the clinical stage. Its sole revenue stream is royalties on AbbVie's hepatitis C regimen MAVYRET, and those royalties dropped to USD 12.9 million this quarter from USD 15.1 million as AbbVie's sales weakened. A 2023 Royalty sale to OMERS, accounted for as debt, takes 54.5% of that stream, which pushed quarterly interest expense to USD 3.5 million from USD 2.4 million. The quarterly loss deepened to USD 23.7 million from USD 18.7 million.

Spending Cuts Shrink the Annual Loss

Quarterly R&D reached USD 26.1 million, up from USD 23.8 million because of higher clinical costs in the RESOLVE and LOTUS RSV studies, yet annual R&D fell to USD 88.5 million from USD 106.7 million on trial timing. G&A for the year slid to USD 36.8 million from USD 43.9 million, reflecting lower share-based pay and reduced legal spending in the Pfizer case. Interest and Investment income dropped to USD 8.2 million from USD 9.4 million amid lower rates. In September the company cut around one-third of its workforce after a strategic review, with the aim of strengthening financial flexibility.

Pipeline Timelines, Patent Setback and CEO Succession

Enrolment has finished in LOTUS, a Phase 2b study of zelicapavir in children with RSV, and topline results are expected in early 2027. Dosing has started in RESOLVE, an adult Phase 2b/3 trial, where Phase 2b data are expected during 2027. Phase 1 results for the KIT inhibitor EDP-978 now arrive in the first quarter of 2027; the STAT6 inhibitor EDP-903 IND moved to the second quarter of 2027 due to a Manufacturing delay, and EPS-5336 targets an IND in the fourth quarter of 2027. The European Unified Patent Court sided against Enanta Pharmaceuticals (NASDAQ:ENTA) in its Pfizer case in October, and a European Patent Office hearing has been scheduled for April 2027. Chief executive Jay Luly, aged 70, is set to step down by February 1, 2027, while Tara Kieffer takes on the Chief Operating Officer role.

Where Things Stand

Yes, on the company's own projection. Management expects USD 194.5 million of cash and marketable securities, along with retained royalty income, to carry operations into fiscal 2029, roughly two years beyond the one-third staff cut. Enanta Pharmaceuticals (NASDAQ:ENTA) still depends on AbbVie's shrinking MAVYRET royalties, which already reduced fiscal 2026 revenue to USD 63.0 million. Next markers include the LOTUS and EDP-978 readouts in early 2027, the April 2027 patent hearing, the CEO search and fiscal first-quarter results due February 8, 2027.